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Abstract
Aims The incidence of gestational diabetes has been reported to have risen over the first decade of this century. Some stud-
ies have also found it to vary with seasons of the year. We investigated temporal and seasonal trends on gestational diabetes 
incidence in a single-centre cohort study from Cambridge, UK, and attempted to explain trends using associated risk factors.
Methods Using a cosinor model, we tested both temporal and seasonal trends in gestational diabetes incidence in 1074 
women recruited to the Cambridge Baby Growth Study in 2001–2009 who underwent oral glucose tolerance tests around 
week 28 of pregnancy.
Results There was a temporal increase in gestational diabetes incidence over the course of recruitment to this study [0.014 
(0.005, 0.022) proportional increase per year, p = 2.1 × 10−3], but no seasonal effect (p = 0.7). HOMA B [− 0.015 (− 0.025, 
− 0.005) per year, p = 3.0 × 10−3] and the insulin disposition index [− 0.036 (− 0.060, − 0.013) per year, p = 3.0 × 10−3], 
unlike HOMA S, showed negative temporal trends. Risk factor analyses showed a concomitant temporal slight increase in 
the index of multiple deprivation [0.191 (0.138, 0.257) units per year, p = 4.6 × 10−10]. This index was positively associated 
with HOMA B (p = 6.1 × 10−5) but not directly with gestational diabetes (p = 0.6), HOMA S (p = 0.2) or the insulin disposi-
tion index (p = 0.4).
Conclusions In this cohort, there were temporal, but not seasonal, increases in gestational diabetes incidence between the 
years 2001 and 2009, which appeared to be related more to reductions in insulin secretion than sensitivity. Possible media-
tors of this link include confounding factors related to deprivation.
Keywords Insulin sensitivity · Pregnancy · Deprivation · Cosinor
Introduction
Gestational diabetes (GDM) is traditionally defined as 
carbohydrate intolerance with its onset or the first recog-
nition in pregnancy [1], although more recent definitions 
explicitly exclude pre-existing type 2 diabetes [2]. It is one 
of the most common adverse conditions of pregnancy. Its 
incidence has generally been reported to be rising in most 
populations, usually in line with the increasing prevalence 
of maternal obesity [3]. Other major risk factors for GDM 
include having a previous history of it or having previously 
given birth to a macrosomic baby, a family history of GDM 
and/or type 2 diabetes, increased maternal age, increased 
gestational weight gain, genetics, multiparity and ethnic 
factors [4], not all of which can explain the tempo of the 
rising incidence. As GDM increases the risk of short- and 
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long-term adverse complications for both the mother and her 
unborn child (including macrosomia, pre-eclampsia, child-
hood obesity and the metabolic syndrome in the mother [5]) 
and may contribute to the diabetes pandemic [6], a thorough 
understanding of its pathogenesis is essential.
With the apparent worldwide rise in the prevalence of 
GDM [7], paralleling the increasing prevalence of female 
obesity [8] of note is the temporal and potentially mecha-
nistic links that obesity has with global warming [9]. There-
fore, another factor that could explain at least part of the 
increased incidence of GDM is exposure to raise or rising 
ambient temperatures in certain populations [10–12]. Fol-
lowing this, some studies have reported seasonal variations 
in the incidence of GDM [13–17], although this has not been 
observed in all populations or climates [18, 19]. In this study 
we investigated whether there were temporal and seasonal 
trends in GDM incidence in our single-centre population 
from Cambridge, UK, which recruited pregnant women 
between 2001 and 2009. We then investigated what may 
have mediated any trends. Although relating to a decade 
ago, this seemed reasonable given that GDM was already 
becoming more prevalent by this time in several different 
populations [20–25].
Materials and methods
Cambridge Baby Growth Study
The prospective, longitudinal Cambridge Baby Growth 
Study (CBGS) was established as an observational cohort 
initially covering pregnancy, birth and infancy [26]. 2229 
mothers, all over 16 years of age, were recruited when 
attending early pregnancy ultrasound clinics at the Rosie 
Maternity Hospital, Cambridge, UK, between April 2001 
and March 2009. A total of 571 of these mothers withdrew 
prior to the birth of their infant. Most of the clinical char-
acteristics of the study participants were collected either 
during nurse-led interviews or by questionnaire with the 
exception of offspring birth weight, gestational age and date 
of birth, which were compiled from hospital notes. In this 
cohort, 95.3% of the offspring were white, 1.7% were Asian, 
1.3% were black (African or Caribbean) and 1.7% were other 
ethnicities (mainly mixed race), reflective of the population 
served by the Rosie Maternity Hospital.
Ethics
The Cambridge Baby Growth Study was approved by the 
Cambridge Local Research Ethics Committee, Adden-
brooke’s Hospital, Cambridge, UK (00/325). All proce-
dures followed were in accordance with the institutional 
guidelines. Written informed consent was obtained from all 
the study participants.
Oral glucose tolerance test and gestational diabetes 
diagnostic criteria
At a median (inter-quartile range) of 28.4 (28.1–28.7) weeks 
gestation, 1074 of the CBGS mothers underwent a 75-g oral 
glucose tolerance test (OGTT) after fasting overnight [27]. 
Venous blood was collected just prior to and 60 min after 
the glucose load was administered for the measurement 
of plasma glucose, insulin and c-peptide concentrations. 
120 min plasma glucose concentrations were only meas-
ured from May 2007 onwards so were not used in this study 
to define GDM (only 7% of UK women with GDM receive 
a diagnosis based solely on the 120-min measurement in 
any case [28]). The International Association of Diabetes 
in Pregnancy Study Groups (IADPSG) thresholds for 0 
and 60 min. OGTT glucose concentrations (i.e. ≥ 5.1 and 
10.0 mmol/L, respectively [29]) were used to define the pres-
ence of GDM.
Assays
All biochemical kit-based assays were run according to the 
manufacturer’s instructions. Glucose concentrations were 
measured using a routine glucose oxidase-based method. 
OGTT plasma insulin concentrations were measured by 
ELISA (Dako UK Ltd., Ely, Cambs, UK). Intra-assay impre-
cision (CV) was 4.3% at 14 mU/L (82 pmol/L), 3.0% at 
67 mU/L (402 pmol/L) and 5.7% at 151 mU/L (907 pmol/L). 
Equivalent inter-assay imprecision was 4.3, 5.1 and 5.4%, 
respectively. C-peptide concentrations were also measured 
by ELISA (DSL Labs., London, UK). Intra-assay impreci-
sion was 2.8% at 1.3 ng/mL (0.43 nmol/L) and at 4.4 ng/
mL (1.47 nmol/L) and 3.2% at 8.4 ng/mL (2.80 nmol/L). 
Equivalent inter-assay imprecision was 15.7, 7.8 and 10.3%, 
respectively.
Calculations
The maternal body mass index (BMI) was calculated as the 
pre-pregnancy weight divided by the height squared. Insu-
lin sensitivity and pancreatic β-cell function were estimated 
using the homeostasis model assessment (HOMA S and B, 
respectively), calculated using the week 28 fasting circulat-
ing glucose and insulin (or c-peptide) concentrations and 
the online HOMA2 calculator (available at https ://www.dtu.
ox.ac.uk/homac alcul ator/) [30]. For this study, HOMA val-
ues were calculated using both insulin and c-peptide concen-
trations separately, and where mentioned in this manuscript 
refer to insulin-derived values unless stated otherwise. Insu-
lin secretion (for a given insulin sensitivity) was assessed 
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in terms of the insulin disposition index, calculated as the 
change in insulin concentrations over the first hour of the 
OGTT divided by the change in glucose concentrations, all 
divided by the reciprocal of the fasting insulin concentration. 
An equivalent disposition index was also calculated using 
plasma c-peptide concentrations. The index of multiple dep-
rivation was derived and imputed from the postcode of the 
participants’ home addresses as described [31].
Statistical analysis
The present analysis was restricted to those 1074 preg-
nancies where the women underwent OGTTs (thereby, 
excluding women with pre-existing type 1 diabetes) with 
0 and 60 min plasma glucose concentrations available to 
us. Data were logarithmically transformed prior to analy-
ses if their distributions were positively skewed. Temporal 
trends, adjusted for seasonal trends, were tested for using the 
cosinor regression model in R (version 3.5.2; The R Project 
for Statistical Computing, Vienna, Austria) deploying the 
package cosinor (version 1.1, available at http://githu b.com/
sachs mc/cosin or) which assumes a sinusoidal seasonal pat-
tern over a longitudinal period, in this case OGTT season 
and year of analysis, respectively. The season was based on 
the month the OGTT was performed using Northern Mete-
orological seasons: winter (December–February), spring 
(March–May), summer (June–August) and autumn (fall) 
(September–November). Further analysis was performed by 
standard logistic (for binary variables) or linear (for continu-
ous variables whose model residuals using untransformed 
or transformed data were normally distributed) regression. 
Nonparametric regression (to fit linear regression models 
that included the index of multiple deprivation due to the 
lack of normal distribution of the residuals in standard 
linear regression models) was performed by means of the 
Siegel repeated medians procedure (deploying the R package 
mblm, version 0.12.1, available at https ://cran.r-proje ct.org/
web/packa ges/mblm/index .html). Categorical analysis was 
performed using the χ2 test. Unless stated, all the other sta-
tistical analyses were performed using Stata (version 13.1; 
Stata Corp., from Timberlake Consultants Ltd., Richmond, 
Surrey, UK). Statistical significance was assumed at p < 0.05 
throughout.
GDM risk factors assessed as above for association with 
year of testing included: BMI, pregnancy weight gain, 
maternal age, offspring birth weight, parity and index of 
multiple deprivation (as continuous variables), and offspring 
sex and multifetal pregnancy (as categorical/binary data).
Results
Characteristics of the study population
With the exception of a slight increase in parity and a 
reduced proportion of smokers, those women who were 
included in the analysis were representative of the Cam-
bridge Baby Growth Study as a whole (Table 1). Variables 
that were not detectably different included GDM prevalence, 
fasting glucose and insulin concentrations, pre-pregnancy 
BMI and maternal age.
Temporal Trends of GDM Incidence and OGTT 
Glucose Concentrations
The overall prevalence of GDM in this population was 
10.1% (108/1071). Cosinor analysis showed a significant 
temporal effect associated with the year of analysis [0.014 
Table 1  Characteristics of those Cambridge Baby Growth Study participants who were included in the current analysis and those that were not
a Adjusted for maternal pre-pregnancy BMI, gestational age at birth, sex of baby and parity. Data are either number of participants or mean (95% 
confidence interval)
Characteristic Included Not included p value
Mother’s age at the birth of her baby (years) 33.4 (33.1, 33.6) (n = 901) 33.8 (33.4, 34.2) (n = 434) 0.06
Parity (n, of increasing parity) 489/373/122/32/6/3 228/267/93/29/2/3 1.2 × 10−4
GDM 110 yes, 967 no 1 yes, 6 no 0.5
OGTT fasting glucose concentration (mmol/L) 4.3 (4.3, 4.4) (n = 1073) 4.2 (3.7, 4.6) (n = 6) 0.5
OGTT fasting insulin concentration (pmol/L) 45.5 (44.0, 47.0) (n = 1053) 46.4 (41.3, 52.1) (n = 83) 0.7
Pre-pregnancy BMI (kg/m2) 23.4 (23.2, 23.7) (n = 830) 23.3 (22.9, 23.7) (n = 357) 0.6
Index of multiple deprivation 8.9 (8.7, 9.1) (n = 1068) 9.0 (8.7, 9.2) (n = 585) 0.9
Maternal highest qualification (category 3/4/5) 80/133/358 33/52/134 0.9
Sex of baby (n males/females) 535/492 320/307 0.7
Baby’s birth weight (kg)a 3.483 (3.454, 3.514) (n = 830) 3.458 (3.412, 3.504) (n = 357) 0.4
Gestational age at birth of baby (weeks) 39.8 (39.7, 39.9) (n = 1029) 39.7 (39.6, 39.8) (n = 628) 0.1
Reported smoking during pregnancy (n yes/no) 40/987 46/582 2.0 × 10−3
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(0.005, 0.022) proportional increase per year, p = 2.1 × 10−3], 
with a trend for the incidence of GDM increasing through 
the years 2001–2009 (Fig. 1). This finding was confirmed by 
logistic regression [odds ratio (OR) 1.2 (1.1, 1.3) per year, 
p = 2.8 × 10−3, n = 1049], even when the small numbers of 
participants collected in 2009 were excluded from the anal-
ysis [OR 1.2 (1.1, 1.3) per year, p = 3.3 × 10−3, n = 1040]. 
There was, however, no significant association of GDM with 
seasonality [amplitude: 9.8 (− 14.7, 34.3), p = 0.4; acrophase 
− 0.6 (− 3.0, 1.9), p = 0.7] (Fig. 1). Cosinor analysis revealed 
no significant association of the OGTT fasting glucose con-
centration with the year [0.009 (− 0.007, 0.025) mmol/L per 
year, p = 0.3] or with seasonality [amplitude: 21.3 (− 24.1, 
66.6), p = 0.4; acrophase − 0.4 (− 2.4, 1.6), p = 0.7]. Con-
versely there was a temporal trend with the OGTT 60-min 
glucose concentrations [0.117 (0.067, 0.166) mmol/L per 
year, p < 1 × 10−4] (Fig. 2), a finding which was confirmed 
by linear regression (β′ = 0.147, p = 1.3 × 10−6, n = 1071), 
without a seasonal effect [amplitude: 53.7 (− 84.1, 191.5), 
p = 0.4; acrophase − 0.9 (− 3.4, 1.7), p = 0.5]. 
Temporal trends of indices of insulin sensitivity 
and secretion
Insulin-derived HOMA S was positively associated with 
the year of testing [0.016 (0.001, 0.032) per year, p = 0.04] 
but not with the season of testing [amplitude: 21.7 (− 20.8, 
64.1), p = 0.3; acrophase 1.3 (− 0.7, 3.4), p = 0.2], a find-
ing which was confirmed by linear regression (β′ = 0.080, 
p = 9.1 × 10−3, n = 1049). This association was still evident 
if adjusting for GDM (p = 3.4 × 10−4, n = 1049) or by only 
including women who were classified as not having GDM 
(p = 1.2 × 10−3; n = 947). However, the association disap-
peared if it were tested using c-peptide-derived HOMA S, 
in a smaller number of women (β′ = 0.014, p = 0.7, n = 929).
Whilst still having a lack of association with seasonality 
[amplitude: 20.9 (− 6.4, 48.2), p = 0.1; acrophase 0.6 (− 0.7, 
1.9), p = 0.4], in contrast to the findings with HOMA S, insu-
lin-derived HOMA B was negatively associated with year of 
testing [− 0.015 (− 0.025, − 0.005) per year, p = 3.0 × 10−3]. 
This association was confirmed by linear regression 
(β′ = − 0.104, p = 7.0 × 10−4, n = 1049). Again, it was still 
evident if adjusting for GDM (p = 1.2 × 10−3, n = 1049) or 
if only including women without GDM (p = 1.2 × 10−3; 
n = 947). This association was still present if it were tested 
using c-peptide-derived HOMA B, in a smaller number of 
women (β′ = − 0.073, p = 0.03, n = 929).
Similar to the results for HOMA B, the insulin disposi-
tion index was negatively associated with year of testing 
[− 0.036 (− 0.060, − 0.013) per year, p = 3.0 × 10−3], a find-
ing which was confirmed by linear regression (β′ = − 0.091, 
p = 3.8 × 10−3, n = 1000). This association was still evident 
if adjusting for GDM (p = 0.03; n = 1000) or if only includ-
ing women without GDM (p = 0.03; n = 905). The insulin 
disposition index was not, however, associated with season 
of testing [amplitude: 26.0 (− 38.5, 90.5), p = 0.4; acrophase 
1.1 (− 1.5, 3.7), p = 0.4]. The c-peptide disposition index was 
also negatively associated with year of testing (β′ = − 0.074, 
p = 0.03, n = 882).
Associations of the year of analysis with potential 
risk factors
The year of analysis was not associated with either the 
maternal BMI (β′ = 0.006, p = 0.9, n = 827) or pregnancy 
weight gain (β′ = − 0.047, p = 0.2, n = 614). Neither was it 
associated with maternal age (β′ = − 0.016, p = 0.6, n = 898) 
or parity (β′ = 0.007, p = 0.8, n = 1022) in this population. 
There was no association between the year of analysis and 
the proportion of male babies (χ2 = 4.9, p = 0.8, n = 1024), 
Fig. 1  a Proportion of women with GDM by the season of the year, 
following an OGTT around week 28 of pregnancy, adjusted for year 
of analysis. Data are means (95% confidence intervals). Analysing 
this data categorically (taking no account of the recurring order of the 
seasons) showed no association between GDM and season of the year 
(χ2 = 2.2, p = 0.5). b Proportion of women with GDM by the year of 
testing, following an OGTT around week 28 of pregnancy
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birth weight of the babies (β′ = − 0.023, p = 0.4, n = 824; 
adjusted for gestational age at birth, mother’s BMI, parity 
and sex) or the odds of a pregnancy being multifetal [OR 
1.0 (0.9, 1.2), p = 0.9, n = 1071]. One potential confounder 
that year of analysis was modestly albeit highly significantly 
associated with, and the index of multiple deprivation [0.191 
(0.138, 0.257) units per year, p = 4.6 × 10−10, n = 1068] 
(Fig. 3) was itself not directly associated with GDM [OR 1.0 
(1.0, 1.1) per unit increase in the index, p = 0.6, n = 1032]. 
There was still a significant relationship between the index 
of multiple deprivation and the year in the reduced num-
ber of 955 women for whom HOMA modelling was avail-
able [0.174 (0.118, 0.237) units per year, p = 5.2 × 10−8]. In 
these women, the index of multiple deprivation was signifi-
cantly positively associated with HOMA B [0.756 (0.376, 
1.143) per unit, p = 6.1 × 10−5; Fig. 3] but not with HOMA 
S [− 0.394 (− 0.967, 0.197) per unit, p = 0.2] or the insulin 
disposition index [43.6 (− 53.8, 150.8) per unit, p = 0.4].
Discussion
In this analysis, there was a strong trend for the incidence 
of GDM increasing as recruitment to the cohort progressed 
between 2001 and 2009. Trends over a similar period of time 
have also been observed in populations in Canada [21], the 
USA [22, 24], Israel [23] and Germany [25]. The worldwide 
increased incidence at that time appeared to be independent 
of ethnicity [20] despite this being a major factor associated 
with GDM risk [4]. In our population, the increased inci-
dence of GDM was associated with reductions in HOMA 
B and the insulin disposition index (rather than HOMA 
S). Whilst a temporal trend in these factors could relate to 
changes in the performance of the insulin and glucose assays 
that were used over time, we used the same assays for these 
analyses throughout this time period and the performance 
characteristics of the insulin assay matched those of similar 
assays available at the time [32]. Given that the performance 
of the glucose assay did not change over this time, the fact 
that the associations with HOMA B and the disposition 
index persisted if they were calculated using c-peptide rather 
than insulin concentrations suggests that these associations 
were physiological rather than assay related. The tempo-
ral increase in GDM incidence in our population therefore 
appeared to relate to reductions in insulin secretion rather 
than sensitivity (indeed insulin-derived HOMA S actually 
increased over the period of recruitment, albeit this associa-
tion was not evident when c-peptide concentrations were 
used to calculate HOMA S in a smaller number of women).
The temporal increase in GDM incidence was clearly 
environmentally mediated as its tempo was too fast for a 
genetic change. In investigating its potential causes and 
the reduced insulin secretion, we could not find parallel 
increases in BMI (itself strongly associated with GDM and 
partially driving the link between factors such as early age 
at menarche and increased GDM risk [33] as has previously 
been observed in our population [34]), pregnancy weight 
gain, maternal age or smoking. There was, however, a sig-
nificant temporal trend of increasing deprivation in the study 
(in a population that was generally less-deprived than the 
national average [26]) although deprivation itself was not 
associated with GDM. There was a modest albeit highly 
Fig. 2  Dot plot of OGTT 
60-min glucose concentrations 
by the year of OGTT testing. 
The bars represent the limits of 
the inter-quartile range of the 
values represented by the dots
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significant positive association between the index of multiple 
deprivation and insulin-derived HOMA B. This suggests that 
in the absence of direct associations with HOMA S or GDM 
risk, as the deprivation index went up pancreatic β-cell func-
tion might have had to increase slightly to maintain glucose 
homeostasis. Due to the lack of direct association between 
the deprivation index and GDM despite the temporal trend, 
it is possible, however, that as yet unidentified confounder(s) 
related to deprivation, such as factors connected with diet 
[35] and/or exercise [36], could have contributed to the tem-
poral increase in GDM incidence. This would be consistent 
with studies where associations between GDM and depriva-
tion, lower socioeconomic status or lower social class were 
reported [25, 37, 38] although such associations have not 
been found in every study [39]. An alternative explanation 
for the temporal trend in deprivation in the present study is 
that it may just reflect unintentional secular patterning in 
study recruitment or uptake.
Although we observed a temporal trend of increasing 
GDM incidence as the decade progressed in this analysis, 
we could not find a seasonal trend. This is despite seasonal 
trends in GDM previously have been observed in popula-
tions in Sweden [13], Australia [14, 15], Italy [16] and 
Greece [17]. However, of the populations tested before 
where no such trend was observed [18, 19], one of these 
was also in the UK [19] so our lack of seasonal trend may 
relate to climate or other environmental factors specific 
to the UK. GDM is known to be a heterogeneous disease 
[40], and the degree of that heterogeneity may be smaller 
when comparing two populations of the same nationality 
Fig. 3  Dot plots of a the index 
of multiple deprivation by year 
of testing and b HOMA B 
values by the index of multiple 
deprivation. The lines of best 
fit (minimising the distance 
between the line and median 
values) were calculated using 
the Siegel repeated medians 
procedure
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and ethnic mix. Alternatively, whilst at least one of the 
studies that found a seasonal trend used a very similar 
analysis technique to the one that we used [15], other stud-
ies used analysis of variance or categorical/ordinal analy-
ses which did not account for the recurring nature of the 
seasons or adjust for longer-term temporal trends [13, 14, 
16, 17] so differences from our results may relate to this.
The strengths of our prospective study include the fact 
that we used cosinor analysis to adjust linear temporal 
trends for separate potential seasonal effects, unlike some 
of the other studies in this area. In addition, we had third 
trimester OGTT data from all the study participants and 
so we were able to investigate whether temporal trends in 
GDM incidence were related to changes in insulin sensi-
tivity or secretion, a level of detail that is rarely available 
in larger surveys. We calculated HOMAs using both insu-
lin and c-peptide concentrations so that detectable tem-
poral trends were less likely to have resulted from drift in 
assay performance. In addition to its strengths, the study 
does have a number of limitations, however. Firstly, this 
Cambridge cohort may not fully reflect the UK popula-
tion as a whole particularly in relation to ethnic mix and 
smoking prevalence [25], although this means that there 
was probably less confounding due to ethnic effects and 
other factors related to the heterogeneity of GDM [40]. 
Secondly, although the study was fairly large given the 
level of detail that was collected, it was smaller than tem-
poral studies of large surveys (e.g. [41]), and therefore, 
the proportion of women who develop GDM in our study 
may be a little unrepresentative of the whole population. 
This could partially account for the large magnitude of the 
increased GDM incidence over the course of the recruit-
ment period in our study. This limitation is offset by the 
level of detail that was collected for each of the study 
participants, however, which allowed us to relate temporal 
changes in the prevalence of GDM to changes in insu-
lin secretion, a finding which has not been attempted in 
larger studies. Thirdly, another limitation is that we did not 
record family histories of GDM and type 2 diabetes, major 
risk factors for GDM [4]. The final limitation of our study 
is that the insulin (and c-peptide) disposition index was 
not calculated using 30 min. OGTT glucose and insulin 
concentrations like usual, but using 60 min concentrations 
instead. Although comparing OGTT results from our study 
with those more commonly from intravenous GTTs, its use 
has been deemed acceptable at least for the insulinogenic 
element of the disposition index [42].
In conclusion, we observed a temporal but not seasonal 
trend for an increasing incidence of GDM in Cambridge 
Baby Growth Study pregnancies from the years 2001–2009. 
This was associated with reductions in indices of insulin 
secretion rather than insulin sensitivity. Although we do not 
know what caused these changes, it does not appear to relate 
to changes in maternal obesity or age. Factors relating to 
deprivation offer potential explanations.
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